RxDoctor Payments Data

Ivan Ayala, MD

Cardiovascular Disease · San Juan, PRNPI 1952345944

Payments from drug & device makers

$4,538in general payments, 2019–2025

Across 106 payments — averaging $42.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Medtronic$702
  • PBG Puerto Rico LLC$541
  • Boehringer Ingelheim$329
  • Amgen$179
  • Boston Scientific$161
  • plus $736 from 12 others

What the payments were for

  • Consulting fees$1,35030%
  • Food & beverage$3,18070%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,538 in reported general payments places this provider in the 60th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$49,751
Medicare patients
174
Services billed
583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban480$404,111
XareltoRivaroxaban390$357,270
FarxigaDapagliflozin Propanediol134$107,182
JardianceEmpagliflozin67$70,028
SynthroidLevothyroxine Sodium623$55,736
JanuviaSitagliptin Phosphate61$51,804
JanumetSitagliptin Phos/Metformin Hcl36$39,888
BrilintaTicagrelor35$27,444
Losartan Potassium1,991$25,005
Metoprolol Succinate1,411$24,757
EntrestoSacubitril/Valsartan23$24,120
Ezetimibe1,125$23,979
Rosuvastatin Calcium1,239$17,651
TradjentaLinagliptin21$17,239
Repatha SureclickEvolocumab30$17,027

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$8$404,111480 claims
Johnson & JohnsonXarelto$1,889$357,270390 claims
AstraZenecaFarxiga, Brilinta$61$134,626169 claims
MerckJanuvia, Janumet, Janumet Xr$98$101,573108 claims
Boehringer IngelheimJardiance, Tradjenta$329$87,26788 claims
NovartisEntresto$100$24,12023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →